PETALING JAYA: Duopharma Biotech Bhd
aims to deliver a satisfactory performance in 2025, barring unforeseen market changes and developments.
In a filing with Bursa Malaysia, Duopharma said this would be achievable with a resolute focus on sustainable growth, cost optimisation and operational resilience.
